Cite
Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement.
MLA
El-Galaly, Tarec Christoffer, et al. “Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging in Newly Diagnosed Classical Hodgkin Lymphoma: Fewer Cases with Stage I Disease and More with Skeletal Involvement.” Leukemia & Lymphoma, vol. 55, no. 10, Oct. 2014, pp. 2349–55. EBSCOhost, https://doi.org/10.3109/10428194.2013.875169.
APA
El-Galaly, T. C., Hutchings, M., Mylam, K. J., Brown, P. de N., Bukh, A., Johnsen, H. E., Kamper, P., Loft, A., Iyer, V., Gormsen, L. C., Nielsen, A. L., Bøgsted, M., & d’Amore, F. (2014). Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leukemia & Lymphoma, 55(10), 2349–2355. https://doi.org/10.3109/10428194.2013.875169
Chicago
El-Galaly, Tarec Christoffer, Martin Hutchings, Karen Juul Mylam, Peter de Nully Brown, Anne Bukh, Hans Erik Johnsen, Peter Kamper, et al. 2014. “Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging in Newly Diagnosed Classical Hodgkin Lymphoma: Fewer Cases with Stage I Disease and More with Skeletal Involvement.” Leukemia & Lymphoma 55 (10): 2349–55. doi:10.3109/10428194.2013.875169.